Evidence map›Paper›PMID 38112867›Full record

Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2023

A randomised trial of topical polaprezinc to prevent oral mucositis in patients undergoing haematopoietic stem cell transplantation (ToPaZ study).

Midori Nakagaki, Glen A Kennedy, Nicole C Gavin, Jason Butler, Alexandra Clavarino, Karen Whitfield

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026
    Review
  3. Oral mucositis management in hematopoietic cell transplantation in Australia and New Zealand (CAN EAT Survey).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Midori NakagakiPharmacy Department, Royal Brisbane and Women's Hospital, Brisbane, Australia. Midori.nakagaki@health.qld.gov.au.ORCID https://orcid.org/0000-0003-4086-6960
Glen A KennedyCancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia.ORCID https://orcid.org/0000-0002-7171-0435
Nicole C GavinCancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia.ORCID https://orcid.org/0000-0002-0828-9852
Jason ButlerCancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia.ORCID https://orcid.org/0000-0002-6422-4404
Alexandra ClavarinoFaculty of Public Health, The University of Queensland, Brisbane, Australia.ORCID https://orcid.org/0000-0002-1145-5946
Karen WhitfieldSchool of Pharmacy, The University of Queensland, Brisbane, Australia.ORCID https://orcid.org/0000-0002-8628-6796
The University of Queensland · AUQueensland University of Technology · AURoyal Brisbane and Women's Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOral mucositis (OM) is a common complication in haematopoietic stem cell transplantation (HSCT). Polaprezinc, an anti-ulcer drug, has been shown to be effective to prevent OM in several studies when administered topically and systemically. This study aimed to evaluate the effectiveness of topical polaprezinc in patients undergoing HSCT.

methodsThis was an open-label randomised clinical trial comparing polaprezinc and sodium bicarbonate mouthwashes for the prevention of severe OM in HSCT patients. Adult patients who received conditioning regimens at moderate to high risk of developing OM were included. The primary endpoint was the incidence of severe (WHO grades 3-4) OM. The secondary endpoints included duration of grades 3-4 OM, incidence and duration of grades 2-4 OM, patient-reported pain and functional limitations.

resultsIn total, 108 patients (55 test arm and 53 control arm) were randomised. There was no difference in the incidence of grades 3 to 4 OM (35% test arm versus 36% control arm). The secondary endpoints were not significantly different. In both arms, patients reported more throat pain compared to mouth pain.

conclusionsTopical polaprezinc had no effect in the prevention of OM in HSCT patients. Further research is required to evaluate the effects of systemic polaprezinc. The OM assessment tool needs to be reviewed as throat mucositis was a main issue in this study.

trial registrationACTRN12320001188921 (Date Registered: 10th November 2020).

Indexed as

CarnosineHematopoietic Stem Cell TransplantationStomatitisAdultHumansOrganometallic CompoundsPainZinc CompoundsCarnosineOrganometallic CompoundspolaprezincZinc CompoundsHaematopoietic stem cell transplantationOral mucositisPolaprezincZinc L-carnosine

Identifiers

PMID38112867
OpenAlexW4389941902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.